Longitudinal outcomes of patients enrolled in a phase Ib clinical trial of the adipose-derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis-Reference-Cited by-同舟云学术

Longitudinal outcomes of patients enrolled in a phase Ib clinical trial of the adipose-derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis

Published:2018-03-12 Issue:6 Volume:12 Page:2084-2089
ISSN:1752-6981
Container-title:The Clinical Respiratory Journal
language:en
Short-container-title:Clin Respir J

Author:

Ntolios Paschalis¹^ORCID,Manoloudi Eleni¹,Tzouvelekis Argyris²,Bouros Evangelos²,Steiropoulos Pachalis¹,Anevlavis Stavros¹,Bouros Demosthenes²,Froudarakis Marios E.¹^ORCID

Affiliation:

1. Department of Respiratory Medicine; Medical School of Alexandroupolis, Democritus University of Thrace; Alexandroupolis Greece

2. First Academic Department of Pneumonology; Hospital for Chest Diseases “Sotiria,” National and Kapodistrian University of Athens; Athens Greece

Publisher

Wiley

Subject

Genetics (clinical),Pulmonary and Respiratory Medicine,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/crj.12777/fullpdf

Reference29 articles.

1. Incidence and prevalence of idiopathic pulmonary fibrosis;Raghu;Am J Respir Crit Care Med.,2006

2. Idiopathic pulmonary fibrosis: an update;Spagnolo;Ann Med.,2015

3. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management;Raghu;Am J Respir Crit Care Med.,2011

4. A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis;Tzouvelekis;J Transl Med.,2013

5. Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER): a phase I safety clinical trial;Glassberg;Chest.,2017

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune mechanisms and novel therapies for idiopathic pulmonary fibrosis;Pharmaceutical Science Advances;2024-12

2. Highlights on Future Treatments of IPF: Clues and Pitfalls;International Journal of Molecular Sciences;2024-08-01

3. Cell-Based Therapy for Fibrosing Interstitial Lung Diseases, Current Status, and Potential Applications of iPSC-Derived Cells;Cells;2024-05-22

4. Mesenchymal stromal cell-based therapy in lung diseases; from research to clinic;American Journal of Stem Cells;2024

5. Cellular therapies for idiopathic pulmonary fibrosis: current progress and future prospects;American Journal of Stem Cells;2024